AAPS PharmSciTech

, 20:322 | Cite as

Controlled Release of Lidocaine–Diclofenac Ionic Liquid Drug from Freeze-Thawed Gelatin/Poly(Vinyl Alcohol) Transdermal Patches

  • Pattwat Maneewattanapinyo
  • Alisa Yeesamun
  • Fueangfah Watthana
  • Kamon Panrat
  • Wiwat Pichayakorn
  • Jirapornchai SuksaereeEmail author
Research Article


The objectives of this work were to prepare a 5 wt% lidocaine–diclofenac ionic liquid drug–loaded gelatin/poly(vinyl alcohol) transdermal patch using a freeze/thaw method and to evaluate its physicochemical properties, in vitro release of lidocaine and diclofenac, and stability test. The lidocaine–diclofenac ionic liquid drug was produced by the ion pair reaction between the hydrochloride salts of lidocaine and the sodium salts of diclofenac. The thermal properties of the final drug product were significantly changed from the primary drugs. The ionic liquid drug could be dissolved in water and mixed in a polymer solution. The resulting transdermal patch was then exposed to 10 cycles of freezing and thawing preparation at − 20°C for 8 h and at 25°C for 4 h, respectively. As a result, it was found that the lidocaine–diclofenac ionic liquid drug–loaded transdermal patch showed good physicochemical properties and could feasibly be used in pharmaceutical applications. The lidocaine–diclofenac ionic liquid drug was not affected by the properties of the transdermal patch due to the lack of chemical interaction between polymer base and drug. The high drug release values of both lidocaine and diclofenac were controlled by the gelatin/poly(vinyl alcohol) transdermal patch. The patch showed good stability over the study period of 3 months when kept at 4°C or under ambient temperature.


ionic liquid drug lidocaine diclofenac transdermal patch characterization 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Moniruzzaman M, Kamiya N, Goto M. Ionic liquid based microemulsion with pharmaceutically accepted components: formulation and potential applications. J Colloid Interface Sci. 2010;352(1):136–42. Scholar
  2. 2.
    Brennecke JF, Maginn EJ. Ionic liquids: innovative fluids for chemical processing. AICHE J. 2001;47(11):2384–9. Scholar
  3. 3.
    Mizuuchi H, Jaitely V, Murdan S, Florence AT. Room temperature ionic liquids and their mixtures: potential pharmaceutical solvents. Eur J Pharm Sci. 2008;33(4):326–31. Scholar
  4. 4.
    Tomasz S, Michal Piotr M, Anna P. Ionic liquids: a new strategy in pharmaceutical synthesis. Mini-Rev Org Chem. 2012;9(2):203–8. Scholar
  5. 5.
    Wilkes JS. A short history of ionic liquids—from molten salts to neoteric solvents. Green Chem. 2002;4(2):73–80. Scholar
  6. 6.
    Shamshina JL, Berton P, Wang H, Zhou X, Gurau G, Rogers RD. Ionic liquids in pharmaceutical industry. Green techniques for organic synthesis and medicinal chemistry. 2018. pp. 539–77. Scholar
  7. 7.
    Marrucho IM, Branco LC, Rebelo LPN. Ionic liquids in pharmaceutical applications. Annu Rev Chem Biomol Eng. 2014;5(1):527–46. Scholar
  8. 8.
    Dobler D, Schmidts T, Klingenhöfer I, Runkel F. Ionic liquids as ingredients in topical drug delivery systems. Int J Pharm. 2013;441(1):620–7. Scholar
  9. 9.
    Huddleston JG, Visser AE, Reichert WM, Willauer HD, Broker GA, Rogers RD. Characterization and comparison of hydrophilic and hydrophobic room temperature ionic liquids incorporating the imidazolium cation. Green Chem. 2001;3(4):156–64. Scholar
  10. 10.
    Moniruzzaman M, Goto M. Ionic liquids: future solvents and reagents for pharmaceuticals. J Chem Eng Jpn. 2011;44(6):370–81. Scholar
  11. 11.
    Pernak J, Sobaszkiewicz K, Mirska I. Anti-microbial activities of ionic liquids. Green Chem. 2003;5(1):52–6. Scholar
  12. 12.
    Moniruzzaman M, Tahara Y, Tamura M, Kamiya N, Goto M. Ionic liquid-assisted transdermal delivery of sparingly soluble drugs. Chem Commun. 2010;46(9):1452–4. Scholar
  13. 13.
    Goindi S, Arora P, Kumar N, Puri A. Development of novel ionic liquid-based microemulsion formulation for dermal delivery of 5-fluorouracil. AAPS PharmSciTech. 2014;15(4):810–21. Scholar
  14. 14.
    Moniruzzaman M, Tamura M, Tahara Y, Kamiya N, Goto M. Ionic liquid-in-oil microemulsion as a potential carrier of sparingly soluble drug: characterization and cytotoxicity evaluation. Int J Pharm. 2010;400(1):243–50. Scholar
  15. 15.
    Zakrewsky M, Lovejoy KS, Kern TL, Miller TE, Le V, Nagy A, et al. Ionic liquids as a class of materials for transdermal delivery and pathogen neutralization. Proc Natl Acad Sci. 2014;111(37):13313–8. Scholar
  16. 16.
    Zhang D, Wang H-J, Cui X-M, Wang C-X. Evaluations of imidazolium ionic liquids as novel skin permeation enhancers for drug transdermal delivery. Pharm Dev Technol. 2017;22(4):511–20. Scholar
  17. 17.
    Jaitely V, Karatas A, Florence AT. Water-immiscible room temperature ionic liquids (RTILs) as drug reservoirs for controlled release. Int J Pharm. 2008;354(1):168–73. Scholar
  18. 18.
    Bica K, Rijksen C, Nieuwenhuyzen M, Rogers RD. In search of pure liquid salt forms of aspirin: ionic liquid approaches with acetylsalicylic acid and salicylic acid. Phys Chem Chem Phys. 2010;12(8):2011–7. Scholar
  19. 19.
    Miwa Y, Hamamoto H, Ishida T. Lidocaine self-sacrificially improves the skin permeation of the acidic and poorly water-soluble drug etodolac via its transformation into an ionic liquid. Eur J Pharm Biopharm. 2016;102:92–100. Scholar
  20. 20.
    Berton P, Di Bona KR, Yancey D, Rizvi SAA, Gray M, Gurau G, et al. Transdermal bioavailability in rats of lidocaine in the forms of ionic liquids, salts, and deep eutectic. ACS Med Chem Lett. 2017;8(5):498–503. Scholar
  21. 21.
    Park HJ, Prausnitz MR. Lidocaine-ibuprofen ionic liquid for dermal anesthesia. AICHE J. 2015;61(9):2732–8. Scholar
  22. 22.
    Hough WL, Smiglak M, Rodríguez H, Swatloski RP, Spear SK, Daly DT, et al. The third evolution of ionic liquids: active pharmaceutical ingredients. New J Chem. 2007;31(8):1429–36. Scholar
  23. 23.
    Maneewattanapinyo P, Suksaeree J. Development and validation of HPLC method for characterization of the acidic and basic drugs prepared into ionic liquid. Lat Am J Pharm. 2019;38(5):961–7.Google Scholar
  24. 24.
    Roy SD, Gutierrez M, Flynn GL, Cleary GW. Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. J Pharm Sci. 1996;85(5):491–5. Scholar
  25. 25.
    Heuschkel S, Goebel A, Neubert RHH. Microemulsions — modern colloidal carrier for dermal and transdermal drug delivery. J Pharm Sci. 2008;97(2):603–31. Scholar
  26. 26.
    Goebel ASB, Knie U, Abels C, Wohlrab J, Neubert RHH. Dermal targeting using colloidal carrier systems with linoleic acid. Eur J Pharm Biopharm. 2010;75(2):162–72. Scholar
  27. 27.
    Alkilani AZ, McCrudden MTC, Donnelly RF. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015;7(4):438–70. Scholar
  28. 28.
    Hassan CM, Peppas NA. Structure and applications of Poly(vinyl alcohol) hydrogels produced by conventional crosslinking or by freezing/thawing methods. In: Chang JY, Godovsky DY, Han MJ, Hassan CM, Kim J, Lee B, et al., editors. Biopolymers PVA hydrogels, anionic polymerisation nanocomposites. Berlin Heidelberg: Springer; 2000. p. 37–65.CrossRefGoogle Scholar
  29. 29.
    Hassan CM, Peppas NA. Structure and morphology of freeze/thawed PVA hydrogels. Macromolecules. 2000;33(7):2472–9. Scholar
  30. 30.
    Martínez YN, Cavello I, Hours R, Cavalitto S, Castro GR. Immobilized keratinase and enrofloxacin loaded on pectin PVA cryogel patches for antimicrobial treatment. Bioresour Technol. 2013;145:280–4. Scholar
  31. 31.
    Gonzalez JS, Martínez YN, Castro GR, Alvarez VA. Preparation and characterization of polyvinyl alcohol–pectin cryogels containing enrofloxacin and keratinase as potential transdermal delivery device. Adv Mater Lett. 2016;7(8):640–5.CrossRefGoogle Scholar
  32. 32.
    Ah Y-C, Choi J-K, Choi Y-K, Ki H-M, Bae J-H. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization. Int J Pharm. 2010;385(1-2):12–9. Scholar
  33. 33.
    Cilurzo F, Minghetti P, Casiraghi A, Tosi L, Pagani S, Montanari L. Polymethacrylates as crystallization inhibitors in monolayer transdermal patches containing ibuprofen. Eur J Pharm Biopharm. 2005;60(1):61–6. Scholar
  34. 34.
    Jain P, Banga AK. Inhibition of crystallization in drug-in-adhesive-type transdermal patches. Int J Pharm. 2010;394(1–2):68–74. Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Chemistry, Faculty of PharmacyRangsit UniversityPathum ThaniThailand
  2. 2.Pharmaceutical Laboratory Service Center, Faculty of Pharmaceutical SciencesPrince of Songkla UniversitySongkhlaThailand
  3. 3.Department of Pharmaceutical Technology, Faculty of Pharmaceutical SciencesPrince of Songkla UniversitySongkhlaThailand

Personalised recommendations